Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | - |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | - |
ClearBridge Large Cap Growth Strategy significantly underperformed the Russell 1000 Growth Index in 2025, trailing by approximately 900 basis points as the benchmark surged 18.6%. The primary headwind was underweights to mega cap AI beneficiaries like Alphabet and Broadcom, along with poor stock selection in healthcare including exits from UnitedHealth Group and Eli Lilly. While the managers correctly positioned in Nvidia since 2018, they underestimated the magnitude of AI spending growth and the market's momentum-driven rally. Post-Liberation Day, they actively repositioned by purchasing Broadcom, Marvell Technology, Datadog and Oracle while exiting lower-conviction names. The managers acknowledge the need to be more proactive when secular themes emerge but believe the current sentiment-driven environment is unsustainable. They expect resurgent growth in the economy ex-tech from fiscal stimulus and easing monetary policy to support broader market participation. The portfolio is being positioned for this transition while maintaining selective exposure to high-quality AI beneficiaries and exploring opportunities in healthcare and short-cycle industrials.
Despite meaningful underperformance due to underweights in mega cap AI beneficiaries, the managers believe the current momentum-driven growth market is unsustainable and are positioning for broader market participation while selectively upgrading AI exposure through higher-quality names.
The managers expect continued AI development with potential for broadening market participation as growth in the economy ex-tech accelerates from fiscal stimulus and easing monetary policy. They anticipate ongoing volatility in AI-related names as monetization models become clearer and are positioning for opportunities in healthcare and short-cycle industrials.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 7 2026 | 2025 Q4 | ACN, ADBE, ANET, AVGO, CMG, DDOG, EQIX, ETN, GOOGL, ISRG, LLY, MRVL, NVDA, ORCL, PLTR, SBUX, TMO, UNH, VRTX, WDAY | AI, growth, healthcare, large cap, momentum, semiconductors, technology, underperformance | - | AI spending exceeded expectations with hyperscalers accelerating capex, emergence of OpenAI and Anthropic as major spending sources, and Alphabet selling custom AI chips to competitors.… |
| Oct 1 2025 | 2025 Q3 | ACN, AVGO, CMG, DDOG, UNH, UNP, WDAY | AI, Broadcom, Datadog, Oracle, technology |
ORCL US DDOG US VRTX US |
The letter discusses dispersion between AI winners and losers, emphasizing disciplined exposure rather than momentum chasing. Infrastructure software and select cyclicals are positioned to benefit… |
| Jul 29 2025 | 2025 Q2 | AIR FP, ICLR, LIN, MRVL, NOW, TSM | AI, Balance Sheets, earnings durability, secular growth, valuation |
TSM MRVL NOW AIR FP LIN ICLR |
The letter emphasizes sustained earnings growth driven by secular themes such as AI adoption, cloud computing and digital transformation. Management highlights high-quality large-cap companies with… |
| Apr 8 2025 | 2025 Q1 | ALC SW, SNPS | - | - | - |
| Jan 7 2025 | 2024 Q4 | ARNB, AVGO, ICON, NEE, NVO, TSLA | - | - | - |
| Sep 30 2024 | 2024 Q3 | ACN, APTV, CMG, EL, NVDA, SBUX, TEAM | - | - | - |
| Jun 30 2024 | 2024 Q2 | PANW, PYPL | - | - | - |
| Apr 20 2024 | 2024 Q1 | PYPL, UNH | - | - | - |
| Mar 1 2024 | 2023 Q4 | AMZN, DXCM, EL, ICE, MFT, NVDA, SPLK, U | - | - | - |
| Nov 10 2023 | 2023 Q3 | EL, LLY, NKE, NVDA, SE, TGT, UNH, UNP, V | - | - | - |
| Jun 30 2023 | 2023 Q2 | ADBE, NVDA | - | - | - |
| Mar 31 2023 | 2023 Q1 | LLY, MSFT, NEE, NVDA | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
AIAI has become a dominant theme across major equity indices, with Nvidia leading the S&P 500, ASML dominating MSCI EAFE, and TSMC leading emerging markets. The fund benefited from AI-related dynamics, particularly through Samsung's memory products experiencing substantial price increases due to DRAM shortages driven by AI demand. |
Semiconductors Memory DRAM Technology Nvidia |
CloudSnowflake was added as the leading player in cloud data storage, providing comprehensive data warehousing services for large businesses. The company's cloud-native platform helps companies store, analyze and share data across organizations, crucial for AI infrastructure upgrades. |
Data Storage Infrastructure Platform Enterprise | |
SemiconductorsTaiwan Semiconductor represents the dominant manufacturer for leading fabless chip designers including NVIDIA, Apple, and Broadcom. The global arms race to develop artificial general intelligence will support multiple years of robust growth for foundries with leading-edge capabilities. |
Foundries Advanced Process AI Chips Manufacturing Technology Leadership | |
TechnologyThe fund added three technology companies that have each halved over 2025 and hopes to add more. Many tech stocks had become expensive but recent falls present opportunities, though most still aren't cheap enough including Xero. |
Software Valuation Opportunity Selloff | |
| 2025 Q3 |
AIAI has become a dominant theme across major equity indices, with Nvidia leading the S&P 500, ASML dominating MSCI EAFE, and TSMC leading emerging markets. The fund benefited from AI-related dynamics, particularly through Samsung's memory products experiencing substantial price increases due to DRAM shortages driven by AI demand. |
Semiconductors Memory DRAM Technology Nvidia |
HealthcareFund focuses exclusively on healthcare sector with concentrated portfolio of small-cap companies. Investment approach targets special situations within healthcare including spin-offs, asset sales, business model pivots, and new product launches. Portfolio includes pharmaceutical, medical device, biotechnology, and healthcare IT companies. |
Pharmaceuticals Medical Devices Biotechnology Healthcare IT Special Situations | |
Technology |
||
| 2025 Q2 |
Growth |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | MRVL | Marvell Technology, Inc. | Information Technology | Semiconductors | Bull | NASDAQ | AI, Interconnect, Networking, semiconductors, valuation | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | NOW | ServiceNow, Inc. | Information Technology | Systems Software | Bull | NYSE | AI, Automation, Margins, SaaS, Workflows | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | AIR FP | Airbus SE | Industrials | Aerospace & Defense | Bull | Euronext Stock Exchange | Aerospace, backlog, cashflow, Defense, Travel | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | LIN | Linde plc | Materials | Industrial Gases | Bull | NYSE | cashflow, Gases, Industrial, Pricing, Space | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | ICLR | ICON plc | Health Care | Life Sciences Tools & Services | Bear | NASDAQ | Funding, Normalization, Outsourcing, Pipelines, visibility | Login |
| Oct 1, 2025 | Fund Letters | Peter Bourbeau | ORCL US | Oracle Corp. | Information Technology | Systems Software | Bull | NYSE | AI, cloud, FCF, growth, infrastructure, Margins, Software, valuation | Login |
| Oct 1, 2025 | Fund Letters | Peter Bourbeau | DDOG US | Datadog, Inc. | Information Technology | Application Software | Bull | NASDAQ | AI, cloud, growth, innovation, Margins, observability, SaaS | Login |
| Oct 1, 2025 | Fund Letters | Peter Bourbeau | VRTX US | Vertex Pharmaceuticals Inc. | Health Care | Biotechnology | Bull | NASDAQ | Biotech, cash, Cystic fibrosis, growth, Pain, pipeline, R&D, valuation | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | TSM | Taiwan Semiconductor Manufacturing Company Limited | Information Technology | Semiconductors | Bear | NYSE | CapEx, Concentration, Geopolitics, Risk, semiconductors | Login |
| TICKER | COMMENTARY |
|---|---|
| ACN | Accenture is the world's leading IT consultant, with advantages stemming from their depth and breadth across products, geographies, and industries. Their revenue is split roughly in half between IT consulting and managed services. Over the last four years, Accenture's valuation has roughly halved. They've faced headwinds in IT spending and suffered from the perception that they are an AI loser. We believe that AI will cause deflationary pressure in parts of their business, but that it will be more than offset by the work required for enterprises to adopt AI. This is recently evidenced by partnerships with OpenAI and Anthropic. The AI supplier landscape is increasingly fragmented, and corporate customers need significant help adopting these technologies at scale. We believe this will drive AI suppliers and customers into Accenture's arms. The current cyclical pressures are being attributed to structural issues, which we believe is incorrect, creating an attractive long-term set-up. |
| ADBE | Later in the quarter we initiated Adobe, a stock we have held before, where we believe AI is more likely to enhance the product suite than disrupt it. |
| ANET | Arista Networks, Inc. was one of the best Technology sector outperformers in the portfolio. It reported strong quarterly financial results during the fourth quarter. |
| AVGO | Broadcom, a leading semiconductor company and long-term holding, continued to execute well amid strong demand for custom silicon supporting AI workloads. |
| CMG | The top-five detractors from returns were Fiserv, Chipotle, Constellation Software, Roper, and Floor & Décor. In the quarter, we exited Fiserv, Chipotle, and monday.com. |
| EQIX | Data center operator Equinix should benefit from the growing importance of sharing data across clouds, but the returns on a large capital spending project will delay revenue growth acceleration until 2027. We view the company as a later stage AI beneficiary, especially if all the current spending begins to produce a positive return on investment. |
| ETN | Eaton's shares pulled back in August following strong performance through July. Like many companies in the industrials complex, Eaton's results did not exceed very high investor expectations. Moving into 2026, we anticipate accelerated growth for the company that is tied to strong trends in data center, aerospace, and defense markets. |
| GOOGL | I'm willing to go bankrupt rather than lose this race. Larry Page, co-founder of Google |
| ISRG | We were pleased to see patience rewarded with a bounce back in various healthcare concerns such as Intuitive Surgical Inc. (ISRG) and Vertex Pharmaceuticals Inc. (VRTX), which posted meaningful gains. |
| LLY | Healthcare added meaningfully through Eli Lilly following a deal the company did with the US administration to reduce the price of its GLP-1 drugs in exchange for tariff relief. |
| MRVL | We also initiated a position in Marvell Technology which is a fabless semiconductor company that supplies technology necessary to move, store, process and secure data across various end-markets such as data centers, enterprise networks and telecommunications infrastructure. We believe the risk/reward looks compelling and we elected to start a position on the stock's recent pullback. |
| NVDA | Nvidia sits at the top of the S&P 500 as the designer in the AI ecosystem. |
| ORCL | Investor enthusiasm for Oracle's stock in calendar year 2025 was initially driven by several multi-billion-dollar contracts it signed with leading AI companies, including OpenAI and Meta. However, in Q4 sentiment for ORCL's growth prospects shifted to skepticism, as investors began to scrutinize the return profile of the substantial capital investments required to support the approximately $500 billion of contracts signed by Oracle. |
| PLTR | AI-enabled surveillance company Palantir trades at over 100 times sales. |
| SBUX | We also rotated our positioning in the restaurant space by eliminating McDonald's and adding Darden Restaurants and Starbucks. |
| TMO | Thermo Fisher Scientific was up on improved sentiment toward the health care sector. |
| UNH | Exited UnitedHealth Group where we had diminished conviction in the company's growth outlook. |
| VRTX | Vertex Pharmaceuticals benefited from growing optimism around its kidney disease pipeline and continued to demonstrate the value of idiosyncratic, innovation-driven growth. |
| WDAY | Finally, we have exited our relatively small position in Workday. The company's growth has decelerated the past few quarters and the Financials segment of the business (~25% of sales) is growing slower than we believe it should be. This is a company we may revisit at a later date but, for now, feel that we have better opportunities in other areas of the portfolio. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||